Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.
Emma H AllottEricka M EbotKonrad H StopsackAmparo G Gonzalez-FelicianoSarah C MarktKathryn M WilsonThomas U AhearnTravis A GerkeMary K DownerJennifer R RiderStephen P FinnTamara L LotanPhilip W KantoffElizabeth A PlatzMassimo LodaMeir J StampferEdward GiovannucciChristopher J SweeneyLorelei A MucciPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Molecular tumor classification identified PTEN and inflammation/immune activation as potential mechanisms linking statins with lower lethal prostate cancer risk. These findings support a potential causal association and could inform selection of relevant biomarkers for statin clinical trials.